Wall Street Is Sleeping on AstraZeneca’s $9B Hidden Non-Oncology Revenue Goldmine

Posted on by

(SeaPRwire) –

By: Christian Brooks

Most biotech investors fixate on AstraZeneca’s oncology pipeline, and they’re leaving billions on the table. The stock jumped 3.1% on June 4, 2026, to close at $181.80, but Bernstein says 37% more upside is still untapped. The market’s blind spot is its total disregard for AZN’s non-oncology division, which will drive most of the company’s growth over the next five years.
AZN Stock Card

Bernstein reaffirmed its outperform rating with a £186 price target, against the recent £135.54 close. Its 2030 revenue forecast hits $89.06B, 11% above AZN’s own $80B risk-adjusted guidance and 8% above Bloomberg consensus. All projected top-line upside through 2035 comes from non-oncology. Standout drug Wainua has a Bernstein 2035 sales estimate of $4.8B, 170% above the $1.8B consensus. Wainua’s phase 3 CARDIO-TTransform data arrives in the second half of 2026, and U.S. ATTR cardiomyopathy diagnosis rates sit at just 30% today. Oral cholesterol drug AZD0780 has no fasting requirement, a key edge over Merck’s competing candidate. COPD drug Tozorakimab posted positive phase 3 data on March 27, 2026, with peak sales guidance of $3B to $5B against $2B consensus.

The stock’s current P/E of 27.3x sits well below AZN’s five-year median of 34.2x, so valuation remains reasonable even after the recent jump. The only small red flag is $2.2M in insider sales over the past three months with no recorded buying activity. Investors should mark Wainua’s upcoming phase 3 data as the next make-or-break catalyst. A positive readout will push AZN’s market cap up by at least 20% before the end of 2026.

Author bio: Christian Brooks, prominent financial and business lead commentator with 12 years covering global biotech and pharma markets.